Alumis vs Zenas BioPharma
ALMS and ZBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALMS and ZBIO compare
Zenas BioPharma is the larger company, worth 2.1 times as much as Alumis ($1.9B against $871M).
Alumis scores higher on the StockData Score (6 against 1 for Zenas BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALMS | ZBIO |
|---|---|---|
| Size and price | ||
| Market cap | $871M | $1.9B |
| Share price | $6.73 | $28.39 |
| Change, 1 year | 42.9% | 1.4% |
| Beta (5Y) | −1.18 | 0.42 |
| Employees | 224 | 167 |
| StockData Score | ||
| Total score | 6 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 118× | – |
| P/B | 1.9× (better) | 7.5× |
| FCF yield | −40.4% | −12.2% (better) |
| Profitability | ||
| Operating margin | −6204% | – |
| Net margin | −5933% | – |
| FCF margin | −4755% | – |
| Return on equity | −93.6% (better) | −199% |
| Financial health | ||
| Debt / equity | 0.00 | 0.90 (better) |
| Current ratio | 6.74 | 9.93 (better) |
| Altman Z-score | 0.23 (better) | −0.70 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 91.3% | 94.0% |
| Held by insiders | 30.5% | 36.1% |
| Insider net buying, 12 months | $60.1M (better) | $11.4M |
| Short interest, % of float | 11.5% | 28.7% |
Go deeper
- ALMS stock overview
- ALMS income statement
- ALMS valuation and score
- ZBIO stock overview
- ZBIO income statement
- ZBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.